DK0430200T3 - Polypeptidholdigt lægemiddel til subkutan eller intramuskulær applikation - Google Patents

Polypeptidholdigt lægemiddel til subkutan eller intramuskulær applikation

Info

Publication number
DK0430200T3
DK0430200T3 DK90122730.6T DK90122730T DK0430200T3 DK 0430200 T3 DK0430200 T3 DK 0430200T3 DK 90122730 T DK90122730 T DK 90122730T DK 0430200 T3 DK0430200 T3 DK 0430200T3
Authority
DK
Denmark
Prior art keywords
polypeptide
subcutaneous
containing drug
intramuscular application
intramuscular
Prior art date
Application number
DK90122730.6T
Other languages
English (en)
Inventor
Eric-Paul Dr Paques
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6394356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0430200(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Application granted granted Critical
Publication of DK0430200T3 publication Critical patent/DK0430200T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK90122730.6T 1989-11-29 1990-11-28 Polypeptidholdigt lægemiddel til subkutan eller intramuskulær applikation DK0430200T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3939346A DE3939346A1 (de) 1989-11-29 1989-11-29 Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide

Publications (1)

Publication Number Publication Date
DK0430200T3 true DK0430200T3 (da) 1994-09-26

Family

ID=6394356

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90122730.6T DK0430200T3 (da) 1989-11-29 1990-11-28 Polypeptidholdigt lægemiddel til subkutan eller intramuskulær applikation

Country Status (12)

Country Link
US (1) US5691312A (da)
EP (1) EP0430200B1 (da)
JP (1) JP3143470B2 (da)
KR (1) KR910009246A (da)
AT (1) ATE106746T1 (da)
AU (1) AU657466B2 (da)
CA (1) CA2030988C (da)
DE (2) DE3939346A1 (da)
DK (1) DK0430200T3 (da)
ES (1) ES2057339T3 (da)
IE (1) IE64080B1 (da)
PT (1) PT96016B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364839A (en) * 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
EP0803255A4 (en) * 1994-06-03 1999-06-30 Tsumura & Co MEDICINAL COMPOSITION
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
SI1478394T1 (sl) * 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
RU2364609C2 (ru) 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
CN1917861B (zh) 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US20090029147A1 (en) * 2006-06-12 2009-01-29 Aspen Aerogels, Inc. Aerogel-foam composites
ES2640343T3 (es) 2008-04-21 2017-11-02 Novo Nordisk Health Care Ag Composición de transglutaminasa anhidra
KR102143482B1 (ko) 2011-11-30 2020-08-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 펩티드 치료제 및 아미노산을 포함하는 마이크로니들 장치, 이의 제조 및 사용 방법
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
KR20250152679A (ko) 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
PT3528787T (pt) 2016-10-21 2026-03-11 Amgen Inc Formulações farmacêuticas e métodos para produzir as mesmas
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
MX2020013713A (es) 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
EP3924328A1 (en) 2019-02-12 2021-12-22 Radius Pharmaceuticals, Inc. Processes and compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
GB2079292A (en) 1980-07-05 1982-01-20 Speywood Lab Ltd Blood Clotting Factor Production
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
US4656034A (en) * 1985-05-20 1987-04-07 Survival Technology, Inc. Absorption enhancing agents
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4839170A (en) * 1985-10-01 1989-06-13 Survival Technology, Inc. Protein absorption enhancing agents
DE3625090A1 (de) * 1986-07-24 1988-01-28 Behringwerke Ag Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung
DE3643182A1 (de) * 1986-12-18 1988-06-30 Behringwerke Ag Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4
US4857320A (en) 1987-02-19 1989-08-15 Monsanto Company Method of enhancing the solubility of tissue plasminogen activator
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations

Also Published As

Publication number Publication date
PT96016B (pt) 1998-06-30
IE64080B1 (en) 1995-07-12
CA2030988A1 (en) 1991-05-30
KR910009246A (ko) 1991-06-28
ATE106746T1 (de) 1994-06-15
CA2030988C (en) 2004-11-16
JPH03170437A (ja) 1991-07-24
DE59006032D1 (de) 1994-07-14
JP3143470B2 (ja) 2001-03-07
DE3939346A1 (de) 1991-06-06
US5691312A (en) 1997-11-25
IE904292A1 (en) 1991-06-05
AU6702990A (en) 1991-06-06
ES2057339T3 (es) 1994-10-16
EP0430200A1 (de) 1991-06-05
AU657466B2 (en) 1995-03-16
PT96016A (pt) 1991-09-13
EP0430200B1 (de) 1994-06-08

Similar Documents

Publication Publication Date Title
DK0430200T3 (da) Polypeptidholdigt lægemiddel til subkutan eller intramuskulær applikation
TR199802789T2 (xx) Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar.
DE58905835D1 (de) Vorrichtung zur nadellosen, subkutanen Injektion von Medikamenten.
DK292587D0 (da) Kompleks, fremgangsmaade til fremstilling deraf og anvendelser af komplekset
GR3026531T3 (en) Treatment for insulin dependent diabetes.
DK296586D0 (da) Flerrumssproejte
PT83873B (pt) Processo de preparacao de medicamentos contendo hexadecilfosfocolina
ES2124685T3 (es) Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso.
DE3789320D1 (de) Verabreichungsinstrument zum Einführen von festen Medikamenten.
DE3784064D1 (de) Einheitlicher, steriler fluessigkeitsverabreichungszusammenbau und herstellungsverfahren.
IT1151741B (it) Soluzione per dialisi contenente glucosio, aminoacidi e insulina
PT93082A (pt) Processo de producao de um derivado de activador de plaminogenio tissular, de plasmideo de expressao e de medicamento contendo o referido derivado
DK644388A (da) Farmaceutiske praeparater indeholdende 3-hydroxy-smoeresyrederivater
DK135887A (da) Human-vaevstype-plasminogenaktivator-polypeptider og fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
IT8520036A0 (it) Processo per la preparazione biotecnologica di acidi alfa-arilalcanoici otticamente attivi.
DE68916532D1 (de) Varianten von menschlichem gewebeplasminogenaktivator sowie verfahren zu deren herstellung.
NO873699L (no) Polypeptid som er egnet til dempning, behandling og diagnostisering av autoimmune lidelser saasom leddbetennelser.
DK610888D0 (da) Cardiodilatinfragmentet, fremgangsmaade til fremstilling deraf samt dets anvendelse
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
FI851752A0 (fi) 2-amino-3-etoxikarbonylamino-6 -(p-fluorbenzylamino) pyridinglukonat och farmaceutiska produkter som innehaoller detta aemne.
DK427288A (da) Thiomethyl- og sulfinylmethylderivater med mavesyresekretorisk aktivitet, fremgangsmaader til fremstilling heraf samt farmaceutiske midler indeholdende disse
DK246985D0 (da) Triterpenylestere af organiske syrer, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende saadanne triterpenylestere
NO179436C (no) Fremgangsmåte for fremstilling av farmasöytiske produkter for topisk bruk
ES8705230A1 (es) Procedimiento para preparar gamma-globulinas administrables por via intravenosa
IT7924769A0 (it) Derivati di acidi aziridin-2-carbossilici n-sostituiti con attivita'immunostimolante, processi per laloro preparazione e farmaci contenenti tali sostanze.